Prof. Dr. med. et phil. nat. Markus Jörger
Oberarzt Onkologie/Hämatologie
Mitarbeiter Wissenschaftliche Module CTU (Klinische Pharmakologie)
Leitende(r) Arzt/Ärztin
Medizinische Onkologie und Hämatologie · Dept. I
Update of the BIG 1-98 Trial: where do we stand?
Jörger M, Thürlimann B. Update of the BIG 1-98 Trial: where do we stand?. Breast 2009; 18 Suppl 3:S78-82.
01.10.2009Update of the BIG 1-98 Trial: where do we stand?
01.10.2009Breast 2009; 18 Suppl 3:S78-82
Jörger Markus, Thürlimann Beat
Ixabepilon bei lokal fortgeschrittenem oder metastasiertem Mammakarzinom: Neue Behandlungsoptionen nach Taxanen und Anthrazyklinen
Templeton A, Thürlimann B, Jörger M. Ixabepilon bei lokal fortgeschrittenem oder metastasiertem Mammakarzinom: Neue Behandlungsoptionen nach Taxanen und Anthrazyklinen. Schweizer Krebsbulletin 2009:114-117.
18.06.2009Ixabepilon bei lokal fortgeschrittenem oder metastasiertem Mammakarzinom: Neue Behandlungsoptionen nach Taxanen und Anthrazyklinen
18.06.2009Schweizer Krebsbulletin 2009:114-117
Templeton Arnoud, Thürlimann Beat, Jörger Markus
Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer
Smit E, van Zandwijk N, Vincent A, Schellens J, Jörger M, Dingemans A, Eppinga P, Smit H, Biesma B, Burgers S, Groen H. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27:2038-45.
20.04.2009Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer
20.04.2009Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27:2038-45
Smit Egbert F, van Zandwijk Nico, Vincent Andrew, Schellens Jan H, Jörger Markus, Dingemans Anne-Marie C, Eppinga Pier, Smit Hans J M, Biesma Bonne, Burgers Sjaak A, Groen Harry J M
St. Gallen 2009 recommendations on the treatment of early breast cancer: consensus and controversy
Jörger M, Senn H, Thürlimann B. St. Gallen 2009 recommendations on the treatment of early breast cancer: consensus and controversy. magazine of european medical oncology 2009; 2:229-231.
01.01.2009St. Gallen 2009 recommendations on the treatment of early breast cancer: consensus and controversy
01.01.2009magazine of european medical oncology 2009; 2:229-231
Jörger Markus, Senn H J, Thürlimann Beat
Side Effects of Drugs Annual 31
Jörger M, Hartmann K, Kuhn M. Side Effects of Drugs Annual 31 - Drugs acting on the respiratory tract. In: Side Effects of Drugs Annual 31. Oxford UK: Elsevier; Linacre House Jordan Hill, 2009. ISBN 978-0-444-53294-7. S. 309.
01.01.2009Side Effects of Drugs Annual 31
01.01.2009Elsevier; Linacre House Jordan Hill, ISBN 978-0-444-53294-7
Jörger Markus, Hartmann K, Kuhn M
Neue Optionen endokriner Therapieindividualisierung? Pharmakogenetik bei Brustkrebs
Jörger M. Neue Optionen endokriner Therapieindividualisierung? Pharmakogenetik bei Brustkrebs - Leading Opinions. Medizin für die Frau 2009; 1:28-30.
01.01.2009Neue Optionen endokriner Therapieindividualisierung? Pharmakogenetik bei Brustkrebs
01.01.2009Medizin für die Frau 2009; 1:28-30
Jörger Markus
CT-diagnosed mesenteric alterations in patients with non-Hodgkin's lymphoma: a population-based study
Jörger M, Nuessli D, Henz S, Zaunbauer W, Cerny T, Cogliatti S, Gillessen Sommer S. CT-diagnosed mesenteric alterations in patients with non-Hodgkin's lymphoma: a population-based study. Onkologie 2008; 31:514-9.
01.10.2008CT-diagnosed mesenteric alterations in patients with non-Hodgkin's lymphoma: a population-based study
01.10.2008Onkologie 2008; 31:514-9
Jörger Markus, Nuessli Dominique, Henz Samuel, Zaunbauer Wolfgang, Cerny Thomas, Cogliatti Sergio B., Gillessen Sommer Silke
Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes
Ribi K, Stahel R, Ris H, Stupp R, Schmid R, Betticher D, Jörger M, Bodis S, Weder W, Schuller J, Bernhard J, Swiss Group for Clinical Cancer Research SAKK. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung cancer (Amsterdam, Netherlands) 2008; 61:398-404.
01.09.2008Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes
01.09.2008Lung cancer (Amsterdam, Netherlands) 2008; 61:398-404
Ribi Karin, Stahel Rolf A, Ris Hans-Beat, Stupp Roger, Schmid Ralph A, Betticher Daniel, Jörger Markus, Bodis Stephan, Weder Walter, Schuller Jan C, Bernhard Jürg, Swiss Group for Clinical Cancer Research SAKK
Side Effects of Drugs Annual 30
Jörger M, Hartmann K, Kuhn M. Side Effects of Drugs Annual 30 - Drugs acting on the respiratory tract. In: Side Effects of Drugs Annual 30. Oxford UK: Elsevier; Linacre House Jordan Hill, 2008. ISBN 0-444-52767-2.
01.01.2008Side Effects of Drugs Annual 30
01.01.2008Elsevier; Linacre House Jordan Hill, ISBN 0-444-52767-2
Jörger Markus, Hartmann K, Kuhn M
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group
Jörger M, Hollema H, Féty R, Van der Vijgh W, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers A, Twelves C, Beijnen J, Boddy A, Calvert H, Jodrell D, Huitema A, Richel D, Dittrich C, Pavlidis N, Briasoulis E, Vermorken J, Strocchi E, Martoni A, Sorio R, Sleeboom H, Izquierdo M, Schellens J. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clinical cancer research : an official journal of the American Association for Cancer Research 2007; 13:6410-8.
01.11.2007Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group
01.11.2007Clinical cancer research : an official journal of the American Association for Cancer Research 2007; 13:6410-8
Jörger Markus, Hollema Harry, Féty Régine, Van der Vijgh Wjf J F, Hempel Georg, Chatelut Etienne, Karlsson Mats, Wilkins Justin, Tranchand Brigitte, Schrijvers Ad H G J, Twelves Christian, Beijnen Jos H, Boddy Alan V, Calvert Hilary, Jodrell Duncan I, Huitema Alwin D R, Richel Dick J, Dittrich Christian, Pavlidis Nikolas, Briasoulis Evangelos, Vermorken Jan B, Strocchi Elena, Martoni Andrea, Sorio Roberto, Sleeboom Henk P, Izquierdo Miguel A, Schellens Jan H M
Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study
Jörger M, Huitema A, Huizing M, Willemse P, de Graeff A, Rosing H, Schellens J, Beijnen J, Vermorken J. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. British journal of clinical pharmacology 2007; 64:622-33.
01.11.2007Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study
01.11.2007British journal of clinical pharmacology 2007; 64:622-33
Jörger Markus, Huitema A D R, Huizing M T, Willemse P H B, de Graeff A, Rosing H, Schellens J H M, Beijnen J H, Vermorken J B
Increased pulmonary FDG uptake in bleomycin-associated pneumonitis
von Rohr L, Klaeser B, Jörger M, Kluckert T, Cerny T, Gillessen Sommer S. Increased pulmonary FDG uptake in bleomycin-associated pneumonitis. Onkologie 2007; 30:320-3.
01.06.2007Increased pulmonary FDG uptake in bleomycin-associated pneumonitis
01.06.2007Onkologie 2007; 30:320-3
von Rohr Lukas, Klaeser Bernd, Jörger Markus, Kluckert Thomas, Cerny Thomas, Gillessen Sommer Silke
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG
Jörger M, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers A, Twelves C, Beijnen J, Schellens J, Jodrell D, Izquierdo M, Sleeboom H, Huitema A, Richel D, Dittrich C, Pavlidis N, Briasoulis E, Vermorken J, Strocchi E, Martoni A, Sorio R, EORTC-PAMM-NDDG. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clinical pharmacokinetics 2007; 46:1051-68.
01.01.2007Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG
01.01.2007Clinical pharmacokinetics 2007; 46:1051-68
Jörger Markus, Féty Régine, de Bruijn Ernst, Hempel Georg, Karlsson Mats, Tranchand Brigitte, Schrijvers Ad H G J, Twelves Chris, Beijnen Jos H, Schellens Jan H M, Jodrell Duncan I, Izquierdo Miguel A, Sleeboom Henk P, Huitema Alwin D R, Richel Dick J, Dittrich Christian, Pavlidis Nikolas, Briasoulis Evangelos, Vermorken Jan B, Strocchi Elena, Martoni Andrea, Sorio Roberto, EORTC-PAMM-NDDG
Adjuvante Therapie des Kolonkarzinoms
Greuter S, Jörger M, Köberle D. Adjuvante Therapie des Kolonkarzinoms. Onkologie 2007; 3:20-24.
01.01.2007Adjuvante Therapie des Kolonkarzinoms
01.01.2007Onkologie 2007; 3:20-24
Greuter S, Jörger Markus, Köberle Dieter
Probleme langwirkender Betamimetika bei Asthma
Jörger M, Kuhn M. Probleme langwirkender Betamimetika bei Asthma. Pharma-Kritik 2007; 29
01.01.2007Probleme langwirkender Betamimetika bei Asthma
01.01.2007Pharma-Kritik 2007; 29
Jörger Markus, Kuhn M
Increased pulmonary FDG Uptake in Bleomycin-associated pneumonitis
Rohr L, Klaeser B, Jörger M, Kluckert J, Cerny T, Gillessen Sommer S. Increased pulmonary FDG Uptake in Bleomycin-associated pneumonitis. Onkologie 2007:320-323.
01.01.2007Increased pulmonary FDG Uptake in Bleomycin-associated pneumonitis
01.01.2007Onkologie 2007:320-323
Rohr L., Klaeser B, Jörger Markus, Kluckert Jörg-Thomas, Cerny Thomas, Gillessen Sommer Silke
Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate
Brouwers E, Tibben M, Rosing H, Hillebrand M, Jörger M, Schellens J, Beijnen J. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. Journal of mass spectrometry : JMS 2006; 41:1186-94.
01.09.2006Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate
01.09.2006Journal of mass spectrometry : JMS 2006; 41:1186-94
Brouwers E E M, Tibben M M, Rosing H, Hillebrand M J X, Jörger Markus, Schellens J H M, Beijnen J H
Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients
Jörger M, Huitema A, Boogerd W, van der Sande J, Schellens J, Beijnen J. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic & clinical pharmacology & toxicology 2006; 99:133-40.
01.08.2006Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients
01.08.2006Basic & clinical pharmacology & toxicology 2006; 99:133-40
Jörger Markus, Huitema A D R, Boogerd W, van der Sande J J, Schellens J H M, Beijnen J H
Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers
Jörger M, Bosch T, Doodeman V, Beijnen J, Smits P, Schellens J. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. European journal of clinical pharmacology 2006; 62:681-4.
01.08.2006Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers
01.08.2006European journal of clinical pharmacology 2006; 62:681-4
Jörger Markus, Bosch T M, Doodeman V D, Beijnen J H, Smits P H M, Schellens J H M
Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes
Sparidans R, Bosch T, Jörger M, Schellens J, Beijnen J. Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006; 839:45-53.
24.07.2006Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes
24.07.2006Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006; 839:45-53
Sparidans Rolf W, Bosch T M, Jörger Markus, Schellens Jan H M, Beijnen Jos H